Published in Nat Rev Mol Cell Biol on November 01, 2004
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
A dimerization-dependent mechanism drives RAF catalytic activation. Nature (2009) 5.39
Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol (2009) 4.98
Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol (2006) 4.84
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell (2009) 3.85
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol (2008) 3.30
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine. Br J Cancer (2010) 3.25
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer (2010) 2.83
Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol (2011) 2.59
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell (2011) 2.57
Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nat Immunol (2009) 2.48
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 2.42
Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation (2010) 2.37
IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett (2009) 2.35
Noonan syndrome. Lancet (2013) 2.13
Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. J Mol Cell Biol (2010) 2.05
Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat Immunol (2009) 2.00
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta (2007) 1.97
MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond) (2008) 1.95
Protein scaffolds in MAP kinase signalling. Cell Signal (2008) 1.94
Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res (2005) 1.93
HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol (2010) 1.90
Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab (2011) 1.82
Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol (2009) 1.81
Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res (2011) 1.79
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77
Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. Mol Syst Biol (2009) 1.77
Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by multiple positive feedback loops. J Biol Chem (2006) 1.75
The ERK Cascade: Distinct Functions within Various Subcellular Organelles. Genes Cancer (2011) 1.74
Raf family kinases: old dogs have learned new tricks. Genes Cancer (2011) 1.72
Leopard syndrome. Orphanet J Rare Dis (2008) 1.69
BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med (2005) 1.67
Interaction of CagA with Crk plays an important role in Helicobacter pylori-induced loss of gastric epithelial cell adhesion. J Exp Med (2005) 1.66
Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol (2005) 1.66
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J (2010) 1.66
Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta (2007) 1.64
Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol (2010) 1.60
Allosteric activation of functionally asymmetric RAF kinase dimers. Cell (2013) 1.60
IQGAP1 modulates activation of B-Raf. Proc Natl Acad Sci U S A (2007) 1.57
Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res (2010) 1.56
Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS One (2007) 1.56
Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci (2010) 1.54
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature (2013) 1.52
Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat (2009) 1.49
A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol (2009) 1.48
Formation of endothelial lumens requires a coordinated PKCepsilon-, Src-, Pak- and Raf-kinase-dependent signaling cascade downstream of Cdc42 activation. J Cell Sci (2009) 1.47
Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets (2007) 1.44
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell (2014) 1.43
Salp15 binding to DC-SIGN inhibits cytokine expression by impairing both nucleosome remodeling and mRNA stabilization. PLoS Pathog (2008) 1.43
Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. Ann Transl Med (2015) 1.42
Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell (2013) 1.37
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
A KSR/CNK complex mediated by HYP, a novel SAM domain-containing protein, regulates RAS-dependent RAF activation in Drosophila. Genes Dev (2006) 1.35
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest (2014) 1.34
Electrostatic interactions positively regulate K-Ras nanocluster formation and function. Mol Cell Biol (2008) 1.34
The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery. Genes Cancer (2011) 1.32
Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene (2009) 1.31
14-3-3 Proteins: diverse functions in cell proliferation and cancer progression. Semin Cell Dev Biol (2011) 1.31
High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res (2009) 1.29
B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS One (2012) 1.29
Spatial regulation of Raf kinase signaling by RKTG. Proc Natl Acad Sci U S A (2007) 1.29
Non-redundancy within the RAS oncogene family: insights into mutational disparities in cancer. Mol Cells (2009) 1.28
Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res (2008) 1.27
Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci U S A (2013) 1.27
SteC is a Salmonella kinase required for SPI-2-dependent F-actin remodelling. Cell Microbiol (2007) 1.26
Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut (2006) 1.25
Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. Mol Biol Cell (2006) 1.24
Cancer driver mutations in protein kinase genes. Cancer Lett (2008) 1.24
Genetic risk factors for melanoma. Hum Genet (2009) 1.21
Cyclic AMP-mediated cyst expansion. Biochim Biophys Acta (2010) 1.21
Spatially dependent dynamic MAPK modulation by the Nde1-Lis1-Brap complex patterns mammalian CNS. Dev Cell (2013) 1.20
Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase. Cell Res (2010) 1.20
Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res (2007) 1.19
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res (2013) 1.19
Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J (2012) 1.18
A MEK-independent role for CRAF in mitosis and tumor progression. Nat Med (2011) 1.17
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer (2010) 1.14
Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development. J Cell Biol (2008) 1.14
Integrin signaling, cell survival, and anoikis: distinctions, differences, and differentiation. J Signal Transduct (2011) 1.14
Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res (2013) 1.13
Chronic itch development in sensory neurons requires BRAF signaling pathways. J Clin Invest (2013) 1.13
PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice. Gastroenterology (2014) 1.13
Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control. Proc Natl Acad Sci U S A (2006) 1.12
Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell Melanoma Res (2015) 1.12
Small G protein signaling in neuronal plasticity and memory formation: the specific role of ras family proteins. Neuron (2010) 1.12
Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol (2013) 1.10
MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther (2010) 1.08
CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol Cell (2008) 1.08
p38γ and p38δ kinases regulate the Toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation. Proc Natl Acad Sci U S A (2012) 1.08
Differential Regulation of RasGAPs in Cancer. Genes Cancer (2011) 1.07
The novel SAM domain protein Aveugle is required for Raf activation in the Drosophila EGF receptor signaling pathway. Genes Dev (2006) 1.07
Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. Oncogene (2010) 1.07
Cancer cell signaling pathways targeted by spice-derived nutraceuticals. Nutr Cancer (2011) 1.07
DA-Raf1, a competent intrinsic dominant-negative antagonist of the Ras-ERK pathway, is required for myogenic differentiation. J Cell Biol (2007) 1.06
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
Melanoma biology and new targeted therapy. Nature (2007) 10.71
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Guilty as charged: B-RAF is a human oncogene. Cancer Cell (2004) 4.97
Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76
V599EB-RAF is an oncogene in melanocytes. Cancer Res (2004) 4.49
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res (2006) 4.29
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell (2005) 4.24
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell (2011) 4.02
Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med (2010) 3.98
B-RAF is a therapeutic target in melanoma. Oncogene (2004) 3.61
ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell (2011) 2.77
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell (2011) 2.57
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56
Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res (2009) 2.42
New insight into BRAF mutations in cancer. Curr Opin Genet Dev (2007) 2.40
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2005) 2.34
JNK2 is a positive regulator of the cJun transcription factor. Mol Cell (2006) 2.32
ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell (2006) 2.20
Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One (2008) 2.15
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst (2012) 2.01
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J Med Chem (2006) 1.94
Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res (2005) 1.93
Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2011) 1.90
JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A (2012) 1.88
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol (2011) 1.82
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A (2011) 1.82
BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am (2009) 1.74
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res (2005) 1.71
Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol (2005) 1.66
Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF). J Med Chem (2009) 1.65
Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res (2009) 1.63
FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J (2006) 1.61
Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J Biol Chem (2003) 1.58
Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53
The role of B-RAF in melanoma. Cancer Metastasis Rev (2005) 1.53
Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res (2007) 1.50
Ras subcellular localization defines extracellular signal-regulated kinase 1 and 2 substrate specificity through distinct utilization of scaffold proteins. Mol Cell Biol (2008) 1.50
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal (2014) 1.44
V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med (2010) 1.36
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov (2012) 1.33
Metformin: a diabetes drug for cancer, or a cancer drug for diabetics? J Clin Oncol (2012) 1.27
The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol (2004) 1.24
14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity. Mol Cell Biol (2002) 1.20
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther (2008) 1.16
Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum Mol Genet (2009) 1.13
Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol (2013) 1.12
CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol Cell (2008) 1.08
In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res (2007) 1.07
BRAF inactivation drives aneuploidy by deregulating CRAF. Cancer Res (2010) 1.05
Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. Cancer Res (2010) 1.05
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes Dev (2012) 1.04
Combined zebrafish-yeast chemical-genetic screens reveal gene-copper-nutrition interactions that modulate melanocyte pigmentation. Dis Model Mech (2010) 1.04
Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms. Mol Cell Biol (2002) 1.02
Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. Clin Cancer Res (2008) 1.02
Raf inhibitors target ras spatiotemporal dynamics. Curr Biol (2012) 1.00
ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf. Oncogene (2002) 0.98
A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression. Oncogene (2005) 0.97
A mouse model of melanoma driven by oncogenic KRAS. Cancer Res (2010) 0.96
Raf phosphorylation: one step forward and two steps back. Mol Cell (2005) 0.96
Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res (2007) 0.96
The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment Cell Melanoma Res (2014) 0.95
Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res (2005) 0.93
Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring. J Med Chem (2009) 0.92
Calmodulin prevents activation of Ras by PKC in 3T3 fibroblasts. J Biol Chem (2002) 0.91
Is BRAF the Achilles' Heel of thyroid cancer? Clin Cancer Res (2006) 0.91
Genomic characterisation of acral melanoma cell lines. Pigment Cell Melanoma Res (2012) 0.89
Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethality. Pigment Cell Melanoma Res (2009) 0.89
Small molecule inhibitors of BRAF in clinical trials. Bioorg Med Chem Lett (2011) 0.88
Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen. J Biomol Screen (2005) 0.88
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med (2012) 0.87
Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression. Pigment Cell Melanoma Res (2011) 0.87
Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold. J Med Chem (2008) 0.86
Deja Vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov (2013) 0.85
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds. Bioorg Med Chem (2010) 0.85
Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group. J Med Chem (2010) 0.84
MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells. Cancer Res (2013) 0.84
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF. Cancer Res (2010) 0.83
Genetic and cellular mechanisms of oncogenesis. Curr Opin Genet Dev (2010) 0.83
(V600E)Braf::Tyr-CreERT2::K14-Kitl mice do not develop superficial spreading-like melanoma: keratinocyte Kit ligand is insufficient to "translocate" (V600E)Braf-driven melanoma to the epidermis. J Invest Dermatol (2011) 0.81
Cancer: Melanoma troops massed. Nature (2009) 0.81
Taking the stress out of melanoma. Cancer Cell (2009) 0.81
Mind the IQGAP. Cancer Cell (2013) 0.80
Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors. J Med Chem (2010) 0.80
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med (2014) 0.80
BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring. J Med Chem (2010) 0.79
Expression of kinase suppressor of Ras in the normal adult and embryonic mouse. Cell Growth Differ (2002) 0.79
(G12D) NRAS and kinase-dead BRAF cooperate to drive naevogenesis and melanomagenesis. Pigment Cell Melanoma Res (2014) 0.78
Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. Cancer Res (2002) 0.78
BRAF as a therapeutic target: a patent review (2006 - 2012). Expert Opin Ther Pat (2013) 0.77
Methods to improve efficacy in suicide gene therapy approaches: targeting prodrug-activating enzymes carboxypeptidase G2 and nitroreductase to different subcellular compartments. Methods Mol Med (2004) 0.77
New insight puts CRAF in sight as a therapeutic target. Cancer Discov (2011) 0.77
Childhood papillary thyroid cancer as second malignancy after successful treatment of rhabdomyosarcoma. Acta Oncol (2008) 0.76
Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia. Cancer Cell (2011) 0.76